Skip to main content
PACB
NASDAQ Industrial Applications And Services

Annual Report Reveals $546M Net Loss Driven by Major Restructuring and Asset Impairments

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$1.65
Mkt Cap
$492.109M
52W Low
$0.851
52W High
$2.73
52W Position info
94% above low
Off High info
40% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

PACB sits 94% above its 52-week low of $0.851.

Summary

Pacific Biosciences reported a $546.4 million net loss for 2025, largely due to $383.1 million in non-cash restructuring charges and asset impairments as it pivots away from short-read sequencing technology. The company also announced a $50.0 million asset sale to Illumina post-period.


Key Events · Earnings and Guidance · PACB

  • Significant Net Loss Driven by Restructuring

    The company reported a net loss of $546.4 million for fiscal year 2025, a 76% increase from 2024, primarily due to $383.1 million in non-cash restructuring-related charges.

  • Major Asset Impairments and Strategic Pivot

    Restructuring charges include $359.3 million in accelerated amortization of Omniome developed technology and $15.0 million in IPR&D impairment, reflecting a decision to cease development of the high-throughput short-read sequencing platform.

  • Asset Sale to Illumina Post-Period

    Subsequent to year-end, on January 30, 2026, the company completed the disposition of its short-read DNA sequencing technology assets to Illumina Cambridge Limited for $50.0 million in cash, with net proceeds of $48.1 million.

  • Improved Cash Burn from Operations

    Cash used in operating activities improved to $111.2 million in 2025 from $206.1 million in 2024, and the company believes it has sufficient liquidity for the next 12 months.


Analysis · PACB · Industrial Applications And Services

Pacific Biosciences of California, Inc.'s annual report for fiscal year 2025 highlights a substantial net loss of $546.4 million, a significant increase from the prior year, primarily due to $383.1 million in non-cash restructuring-related charges. These charges include accelerated amortization of developed technology from the 2021 Omniome acquisition and impairment of in-process research and development (IPR&D) assets, stemming from a strategic decision to cease development of its high-throughput short-read sequencing platform. While total revenue saw a modest 4% increase and cash used in operating activities improved, the large non-cash write-downs reflect a major strategic pivot and a re-evaluation of past investments. The subsequent sale of short-read DNA sequencing technology to Illumina for $50.0 million provides a cash infusion and further solidifies the company's focus on its HiFi long-read sequencing technology. The company states it has sufficient liquidity for the next 12 months, but the significant losses and strategic shift indicate ongoing challenges and a need for successful execution of its revised strategy.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 48.1% of the 1752 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PACB was trading at $1.65 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $492.1M. The 52-week trading range was $0.85 to $2.73. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PACB - Latest Insights

PACB
Nov 10, 2026, 4:05 PM EST
Filing Type: 424B5
Importance Score:
7
Price at Filing: $2.25
Real-time Price: $2.09 info
Change: -$0.164 (-7%) info
Market Cap: $652.452M info
PACB
Nov 05, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $2.54
Real-time Price: $2.09 info
Change: -$0.455 (-18%) info
Market Cap: $652.452M info
PACB
Nov 04, 2026, 5:41 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $2.60
Real-time Price: $2.09 info
Change: -$0.515 (-20%) info
Market Cap: $652.452M info
PACB
Nov 04, 2026, 4:09 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.68
Real-time Price: $2.09 info
Change: -$0.595 (-22%) info
Market Cap: $652.452M info
PACB
Nov 04, 2026, 4:05 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $2.57
Real-time Price: $2.09 info
Change: -$0.485 (-19%) info
Market Cap: $652.452M info